Cargando…

Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype

Mutations in leucine‐rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease (PD). The LRRK2 physiological and pathological function is still debated. However, different experimental evidence based on LRRK2 cellular localization and LRRK2 protein interactors sugges...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rassu, Mauro, Biosa, Alice, Galioto, Manuela, Fais, Milena, Sini, Paola, Greggio, Elisa, Piccoli, Giovanni, Crosio, Claudia, Iaccarino, Ciro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850958/ https://www.ncbi.nlm.nih.gov/pubmed/31560168 http://dx.doi.org/10.1111/jcmm.14674

Ejemplares similares

Inhibition of the Exocyst Complex Attenuates the LRRK2 Pathological Effects
por: Ciampelli, Cristina, et al.
Publicado: (2023)

Role of LRRK2 in the regulation of dopamine receptor trafficking
por: Rassu, Mauro, et al.
Publicado: (2017)

HDAC1 inhibition ameliorates TDP-43-induced cell death in vitro and in vivo
por: Sanna, Simona, et al.
Publicado: (2020)

LRRK2 Modulates the Exocyst Complex Assembly by Interacting with Sec8
por: Fais, Milena, et al.
Publicado: (2021)

Parkinson’s Disease-Related Genes and Lipid Alteration
por: Fais, Milena, et al.
Publicado: (2021)

Cyanobacteria, Cyanotoxins, and Neurodegenerative Diseases: Dangerous Liaisons
por: Sini, Paola, et al.
Publicado: (2021)

LRRK2 Affects Vesicle Trafficking, Neurotransmitter Extracellular Level and Membrane Receptor Localization
por: Migheli, Rossana, et al.
Publicado: (2013)

Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues
por: Iannotta, Lucia, et al.
Publicado: (2020)

The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A
por: Rivero-Ríos, Pilar, et al.
Publicado: (2019)

The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1
por: Perez Carrion, Maria, et al.
Publicado: (2018)

LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
por: Russo, Isabella, et al.
Publicado: (2014)

Single-step green synthesis and characterization of gold-conjugated polyphenol nanoparticles with antioxidant and biological activities
por: Sanna, Vanna, et al.
Publicado: (2014)

Astroglial Inhibition of NF-κB Does Not Ameliorate Disease Onset and Progression in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
por: Crosio, Claudia, et al.
Publicado: (2011)

LRRK2 modulates neuronal vesicles cycle through protein interactions
por: Piccoli, Giovanni, et al.
Publicado: (2015)

Editorial: LRRK2—Fifteen Years From Cloning to the Clinic
por: Rideout, Hardy, et al.
Publicado: (2022)

LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex
por: Cirnaru, Maria D., et al.
Publicado: (2014)

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
por: Taymans, Jean-Marc, et al.
Publicado: (2016)

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
por: Lobbestael, E., et al.
Publicado: (2016)

A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively
por: Marchand, Antoine, et al.
Publicado: (2022)

The Parkinson's Disease Associated LRRK2 Exhibits Weaker In Vitro Phosphorylation of 4E-BP Compared to Autophosphorylation
por: Kumar, Azad, et al.
Publicado: (2010)

Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson’s disease
por: Iovino, Ludovica, et al.
Publicado: (2022)

Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging
por: Longo, Francesco, et al.
Publicado: (2014)

PAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2
por: Civiero, Laura, et al.
Publicado: (2017)

LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate
por: Belluzzi, Elisa, et al.
Publicado: (2016)

LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias
por: Stanic, Jennifer, et al.
Publicado: (2016)

Pathological Functions of LRRK2 in Parkinson’s Disease
por: Jeong, Ga Ram, et al.
Publicado: (2020)

LRRK2 along the Golgi and lysosome connection: a jamming situation
por: Piccoli, Giovanni, et al.
Publicado: (2021)

GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2
por: Blanca Ramírez, Marian, et al.
Publicado: (2017)

The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity
por: Stormo, Adrienne E.D., et al.
Publicado: (2022)

MAP1B rescues LRRK2 mutant-mediated cytotoxicity
por: Chan, Sharon L, et al.
Publicado: (2014)

LRRK2 Regulates Voltage-Gated Calcium Channel Function
por: Bedford, Cade, et al.
Publicado: (2016)

Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous Lrrk2 mutations and ameliorated by Lrrk2 genetic knock-out
por: MacIsaac, Sarah, et al.
Publicado: (2020)

Parkinson’s Disease–Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance
por: Streubel-Gallasch, Linn, et al.
Publicado: (2021)

Expression Analysis of Lrrk1, Lrrk2 and Lrrk2 Splice Variants in Mice
por: Giesert, Florian, et al.
Publicado: (2013)

Levetiracetam in the treatment of epilepsy
por: Abou-Khalil, Bassel
Publicado: (2008)

Levetiracetam-induced pancytopenia
por: Alzahrani, Talal, et al.
Publicado: (2015)

The LRRK2 signalling system
por: Price, Alice, et al.
Publicado: (2018)

Temporal Expression of Mutant LRRK2 in Adult Rats Impairs Dopamine Reuptake
por: Zhou, Hongxia, et al.
Publicado: (2011)

LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease
por: Chang, Eunice Eun Seo, et al.
Publicado: (2022)

Levetiracetam alleviates cognitive decline in Alzheimer’s disease animal model by ameliorating the dysfunction of the neuronal network
por: Zheng, Xiang-Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_case87ds0fug63r15r84k39ir1